{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:03:17Z","timestamp":1770825797788,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00120-025-02753-9","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:24:17Z","timestamp":1766503457000},"page":"186-194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapieoptionen bei seltenen urologischen Tumoren: Perspektiven durch molekulare Tumorboards","Treatment options in rare urological tumors: potential of molecular tumor boards"],"prefix":"10.1007","volume":"65","author":[{"given":"Steffen","family":"Rausch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Linxweiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"10","key":"2753_CR1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00432-024-05983-0","volume":"150","author":"D Heimdorfer","year":"2024","unstructured":"Heimdorfer\u00a0D, Artamonova\u00a0N, Culig\u00a0Z, Heidegger\u00a0I (2024) Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer. J\u00a0Cancer Res Clin Oncol 150(10):462","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2753_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.21037\/tau-23-541","volume":"13","author":"N Artamonova","year":"2024","unstructured":"Artamonova\u00a0N, Djanani\u00a0A, Schmiederer\u00a0A et\u00a0al (2024) Small cell neuroendocrine prostate cancer with adenocarcinoma components\u2014case report and literature review. Transl Androl Urol 13(5):868\u2013878","journal-title":"Transl Androl Urol"},{"issue":"24","key":"2753_CR3","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal\u00a0R, Huang\u00a0J, Alumkal\u00a0JJ et\u00a0al (2018) Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A\u00a0Multi-institutional Prospective Study. J\u00a0Clin Oncol 36(24):2492\u20132503","journal-title":"J Clin Oncol"},{"issue":"1","key":"2753_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","volume":"41","author":"L Merkens","year":"2022","unstructured":"Merkens\u00a0L, Sailer\u00a0V, Lessel\u00a0D et\u00a0al (2022) Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. J\u00a0Exp Clin Cancer Res 41(1):46","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2753_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran\u00a0H, Rickman\u00a0DS, Park\u00a0K et\u00a0al (2011) Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1(6):487\u2013495","journal-title":"Cancer Discov"},{"issue":"2","key":"2753_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada\u00a0Y, Beltran\u00a0H (2021) Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep 23(2):15","journal-title":"Curr Oncol Rep"},{"issue":"24","key":"2753_CR7","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-15-0744","volume":"21","author":"H Tsai","year":"2015","unstructured":"Tsai\u00a0H, Morais\u00a0CL, Alshalalfa\u00a0M et\u00a0al (2015) Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res 21(24):5619\u20135629","journal-title":"Clin Cancer Res"},{"key":"2753_CR8","doi-asserted-by":"crossref","unstructured":"von Amsberg G, Zilles M, Mansour W et\u00a0al (2022) Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci 23(23)","DOI":"10.3390\/ijms232314948"},{"key":"2753_CR9","doi-asserted-by":"crossref","unstructured":"Aggarwal R, Rottey S, Bernard-Tessier A et\u00a0al (2025) Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase\u00a01b DeLLpro-300 Study. Clin Cancer Res","DOI":"10.1158\/1078-0432.c.8034676"},{"key":"2753_CR10","unstructured":"- (2022) ST T. BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype\u2014Phase\u00a02a interim results. J\u00a0Clin Oncol 40(6)"},{"key":"2753_CR11","doi-asserted-by":"crossref","unstructured":"Beltran H (2024) Updated results from a\u00a0phase\u00a01\/2\u00a0study of HPN328, a\u00a0tri-specific, half-life (T1\/2) extended DLL3-targeting T\u2011cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). J\u00a0Clin Oncol 42:","DOI":"10.1200\/JCO.2024.42.16_suppl.8090"},{"issue":"1","key":"2753_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran\u00a0H, Oromendia\u00a0C, Danila\u00a0DC et\u00a0al (2019) A\u00a0Phase\u00a0II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res 25(1):43\u201351","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2753_CR13","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.21037\/tcr-24-737","volume":"13","author":"MJ Pierro","year":"2024","unstructured":"Pierro\u00a0MJ, Gallan\u00a0A, Kilari\u00a0D (2024) Non-clear cell renal cell carcinoma narrative review: where we are in 2024. Transl Cancer Res 13(11):6403\u20136412","journal-title":"Transl Cancer Res"},{"issue":"6 Pt 1","key":"2753_CR14","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1097\/01.ju.0000096060.92397.ed","volume":"170","author":"WM Linehan","year":"2003","unstructured":"Linehan\u00a0WM, Walther\u00a0MM, Zbar\u00a0B (2003) The genetic basis of cancer of the kidney. J\u00a0Urol 170(6 Pt 1):2163\u20132172","journal-title":"J Urol"},{"issue":"1","key":"2753_CR15","first-page":"23","volume":"115","author":"A Calio","year":"2022","unstructured":"Calio\u00a0A, Marletta\u00a0S, Brunelli\u00a0M, Martignoni\u00a0G (2022) WHO 2022 Classification of Kidney Tumors: what is relevant? An update and future novelties for the pathologist. Pathologica 115(1):23\u201331","journal-title":"Pathologica"},{"issue":"3","key":"2753_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","volume":"26","author":"CF Davis","year":"2014","unstructured":"Davis\u00a0CF, Ricketts\u00a0CJ, Wang\u00a0M et\u00a0al (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26(3):319\u2013330","journal-title":"Cancer Cell"},{"issue":"1","key":"2753_CR17","doi-asserted-by":"publisher","first-page":"110190","DOI":"10.1016\/j.celrep.2021.110190","volume":"38","author":"Z Bakouny","year":"2022","unstructured":"Bakouny\u00a0Z, Sadagopan\u00a0A, Ravi\u00a0P et\u00a0al (2022) Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep 38(1):110190","journal-title":"Cell Rep"},{"issue":"6","key":"2753_CR18","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","volume":"27","author":"G Sun","year":"2021","unstructured":"Sun\u00a0G, Zhang\u00a0X, Liang\u00a0J et\u00a0al (2021) Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. Clin Cancer Res 27(6):1734\u20131743","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2753_CR19","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.24.00767","volume":"42","author":"P Barata","year":"2024","unstructured":"Barata\u00a0P, Tangen\u00a0C, Plets\u00a0M et\u00a0al (2024) Final Overall Survival Analysis of S1500: A\u00a0Randomized, Phase\u00a0II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J\u00a0Clin Oncol 42(33):3911\u20133916","journal-title":"J Clin Oncol"},{"issue":"9","key":"2753_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.20.02365","volume":"39","author":"DF McDermott","year":"2021","unstructured":"McDermott\u00a0DF, Lee\u00a0JL, Ziobro\u00a0M et\u00a0al (2021) Open-Label, Single-Arm, Phase\u00a0II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J\u00a0Clin Oncol 39(9):1029\u20131039","journal-title":"J Clin Oncol"},{"issue":"8","key":"2753_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges\u00a0L, Gurney\u00a0H, Atduev\u00a0V et\u00a0al (2023) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet Oncol 24(8):881\u2013891","journal-title":"Lancet Oncol"},{"issue":"2","key":"2753_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.eururo.2021.03.015","volume":"80","author":"TE Hutson","year":"2021","unstructured":"Hutson\u00a0TE, Michaelson\u00a0MD, Kuzel\u00a0TM et\u00a0al (2021) A\u00a0Single-arm, Multicenter, Phase\u00a02\u00a0Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol 80(2):162\u2013170","journal-title":"Eur Urol"},{"issue":"2","key":"2753_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00345-008-0302-z","volume":"27","author":"MC Bleeker","year":"2009","unstructured":"Bleeker\u00a0MC, Heideman\u00a0DA, Snijders\u00a0PJ, Horenblas\u00a0S, Dillner\u00a0J, Meijer\u00a0CJ (2009) Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 27(2):141\u2013150","journal-title":"World J Urol"},{"issue":"7","key":"2753_CR24","doi-asserted-by":"publisher","first-page":"e34874","DOI":"10.2196\/34874","volume":"8","author":"L Fu","year":"2022","unstructured":"Fu\u00a0L, Tian\u00a0T, Yao\u00a0K et\u00a0al (2022) Global Pattern and Trends in Penile Cancer Incidence: Population-Based Study. JMIR Public Health Surveill 8(7):e34874","journal-title":"JMIR Public Health Surveill"},{"key":"2753_CR25","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge des Peniskarzinoms, Langversion 1.0, 2020, AWMF Registernummer: 043-042OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/peniskarzinom\/ (EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3)"},{"key":"2753_CR26","doi-asserted-by":"crossref","unstructured":"Mink JN, Khalmurzaev O, Pryalukhin A et\u00a0al (2023) Evaluation of Prognostic Parameters to Identify Aggressive Penile Carcinomas. Cancers 15(19)","DOI":"10.3390\/cancers15194748"},{"key":"2753_CR27","volume-title":"presented at the EAU Annual Congress Paris","author":"EAU Guidelines","year":"2024","unstructured":"EAU Guidelines (2024) presented at the EAU Annual Congress Paris (978-94-92671-23-3)"},{"issue":"2","key":"2753_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/MOU.0000000000000712","volume":"30","author":"A Thomas","year":"2020","unstructured":"Thomas\u00a0A, Vanthoor\u00a0J, Vos\u00a0G, Tsaur\u00a0I, Albersen\u00a0M (2020) Risk factors and molecular characterization of penile cancer: impact on prognosis and potential targets for systemic therapy. Curr Opin Urol 30(2):202\u2013207","journal-title":"Curr Opin Urol"},{"issue":"1","key":"2753_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch\u00a0H, Cubilla\u00a0AL, Humphrey\u00a0PA, Reuter\u00a0VE, Ulbright\u00a0TM (2016) The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part\u00a0A:\u00a0Renal, Penile, and Testicular Tumours. Eur Urol 70(1):93\u2013105","journal-title":"Eur Urol"},{"issue":"5","key":"2753_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto\u00a0GJ, Amin\u00a0MB, Berney\u00a0DM et\u00a0al (2022) The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part\u00a0B:\u00a0Prostate and Urinary Tract Tumors. Eur Urol 82(5):469\u2013482","journal-title":"Eur Urol"},{"issue":"4","key":"2753_CR31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/a-2104-1270","volume":"54","author":"JN Mink","year":"2023","unstructured":"Mink\u00a0JN, Khalmurzaev\u00a0O, Pryalukhin\u00a0A et\u00a0al (2023) Importance of HPV status and p16 for the prognosis of penile carcinoma. Aktuelle Urol 54(4):274\u2013284","journal-title":"Aktuelle Urol"},{"issue":"10","key":"2753_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Valderrama\u00a0BP, Gupta\u00a0S et\u00a0al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N\u00a0Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"6","key":"2753_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.eururo.2024.03.001","volume":"85","author":"J Linxweiler","year":"2024","unstructured":"Linxweiler\u00a0J, Kl\u00fcmper\u00a0N, Mink\u00a0J, Eckstein\u00a0M, Junker\u00a0K (2024) Re: Assessment of PD-L1, TROP2, and NECTIN\u20114 Expression in Penile Squamous Cell Carcinoma. Eur Urol 85(6):586\u2013587","journal-title":"Eur Urol"},{"issue":"10","key":"2753_CR34","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid\u00a0PM, Satpayev\u00a0D, Yang\u00a0P et\u00a0al (2016) Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin\u20114 Is a\u00a0Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 76(10):3003\u20133013","journal-title":"Cancer Res"},{"key":"2753_CR35","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Murata M, Shen CH, Furue M, Ito T (2021) NECTIN4: A\u00a0Novel Therapeutic Target for Melanoma. Int J Mol Sci 22(2)","DOI":"10.3390\/ijms22020976"},{"issue":"4","key":"2753_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s11864-022-00940-w","volume":"23","author":"H Hashimoto","year":"2022","unstructured":"Hashimoto\u00a0H, Tanaka\u00a0Y, Murata\u00a0M, Ito\u00a0T (2022) Nectin-4: a\u00a0Novel Therapeutic Target for Skin Cancers. Curr Treat Options Oncol 23(4):578\u2013593","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"2753_CR37","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Klumper","year":"2023","unstructured":"Klumper\u00a0N, Ralser\u00a0DJ, Ellinger\u00a0J et\u00a0al (2023) Membranous NECTIN\u20114 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res 29(8):1496\u20131505","journal-title":"Clin Cancer Res"},{"key":"2753_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.12.008","volume":"49","author":"GD Grass","year":"2023","unstructured":"Grass\u00a0GD, Chahoud\u00a0J, Lopez\u00a0A et\u00a0al (2023) An Analysis of Nectin\u20114 (PVRL4) in Penile Squamous Cell Carcinoma. Eur Urol Open Sci 49:1\u20135","journal-title":"Eur Urol Open Sci"},{"key":"2753_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","volume":"142","author":"B Tekin","year":"2023","unstructured":"Tekin\u00a0B, Cheville\u00a0JC, Herrera Hernandez\u00a0L et\u00a0al (2023) Assessment of PD-L1, TROP2, and nectin\u20114 expression in penile squamous cell carcinoma. Hum Pathol 142:42\u201350","journal-title":"Hum Pathol"},{"key":"2753_CR40","unstructured":"Mink JNEM, Khalmurzaev O Evaluation of Nectin\u20114 and Trop-2: implications for patient outcomes and therapy in penile cancer. Mod Pathol (doi: Accepted for publication)"},{"key":"2753_CR41","doi-asserted-by":"crossref","unstructured":"Fahey CC, Nebhan CA, York S et\u00a0al (2023) Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin. Int J Mol Sci 24(22)","DOI":"10.3390\/ijms242216109"},{"key":"2753_CR42","doi-asserted-by":"crossref","unstructured":"Pagliaro LC, Moore CN, Tan W et\u00a0al (2024) A\u00a0phase\u00a0II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis. JCO 42(16) (suppl): TPS5108-TPS)","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5108"},{"issue":"4","key":"2753_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bju.16442","volume":"134","author":"R Weiten","year":"2024","unstructured":"Weiten\u00a0R, Storz\u00a0E, Kessler\u00a0C et\u00a0al (2024) Trophoblast cell surface antigen-2: a\u00a0promising new biomarker and potential therapeutic target in penile squamous cell carcinoma. BJU Int 134(4):615\u2013621","journal-title":"BJU Int"},{"key":"2753_CR44","doi-asserted-by":"crossref","unstructured":"Kydd AR, Chandran E, Simon NI et\u00a0al (2024) SMART: A\u00a0phase\u00a0II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder\/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer. JCO 42(16) (TPS4627-TPS)","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4627"},{"key":"2753_CR45","doi-asserted-by":"publisher","first-page":"113360","DOI":"10.1016\/j.ejca.2023.113360","volume":"194","author":"X Tan","year":"2023","unstructured":"Tan\u00a0X, Wang\u00a0Y, Wu\u00a0Z et\u00a0al (2023) The role of Her\u20112 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy. Eur J Cancer 194:113360","journal-title":"Eur J Cancer"},{"issue":"9","key":"2753_CR46","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","volume":"27","author":"AM Udager","year":"2016","unstructured":"Udager\u00a0AM, Liu\u00a0TY, Skala\u00a0SL et\u00a0al (2016) Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol 27(9):1706\u20131712","journal-title":"Ann Oncol"},{"issue":"5","key":"2753_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.2025.43.5_suppl.9","volume":"43","author":"A Challapalli","year":"2025","unstructured":"Challapalli\u00a0A, Bahl\u00a0A, Venugopal\u00a0B et\u00a0al (2025) EPIC-B:\u00a0Phase\u00a0II trial of cemiplimab as first-line treatment in advanced penile carcinoma. JCO 43(5):9","journal-title":"JCO"},{"issue":"31","key":"2753_CR48","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1200\/JCO.22.02894","volume":"41","author":"HM de Vries","year":"2023","unstructured":"de Vries\u00a0HM, Rafael\u00a0TS, Gil-Jimenez\u00a0A et\u00a0al (2023) Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A\u00a0Phase\u00a0II Trial. J\u00a0Clin Oncol 41(31):4872\u20134880","journal-title":"J Clin Oncol"},{"issue":"2","key":"2753_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.euo.2024.04.021","volume":"8","author":"X Garcia Del Muro","year":"2025","unstructured":"Garcia Del Muro\u00a0X, Paez Lopez-Bravo\u00a0D, Cuellar-Rivas\u00a0MA et\u00a0al (2025) Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase\u00a02 ORPHEUS Study. Eur Urol Oncol 8(2):278\u2013286","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"2753_CR50","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2024.03.038","volume":"86","author":"L Elst","year":"2024","unstructured":"Elst\u00a0L, Philips\u00a0G, Vandermaesen\u00a0K et\u00a0al (2024) Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a\u00a0Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization. Eur Urol 86(2):114\u2013127","journal-title":"Eur Urol"},{"issue":"12","key":"2753_CR51","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.humpath.2013.07.012","volume":"44","author":"A Chaux","year":"2013","unstructured":"Chaux\u00a0A, Munari\u00a0E, Katz\u00a0B et\u00a0al (2013) The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a\u00a0tissue microarray and digital image analysis study of 112 cases. Hum Pathol 44(12):2690\u20132695","journal-title":"Hum Pathol"},{"key":"2753_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.humpath.2016.07.041","volume":"61","author":"SAM Amancio","year":"2017","unstructured":"Amancio\u00a0SAM, Cunha\u00a0IW, Neves\u00a0JI et\u00a0al (2017) Epidermal growth factor receptor as an adverse survival predictor in squamous cell carcinoma of the penis. Hum Pathol 61:97\u2013104","journal-title":"Hum Pathol"},{"issue":"6","key":"2753_CR53","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/bju.12450","volume":"113","author":"BC Carthon","year":"2014","unstructured":"Carthon\u00a0BC, Ng\u00a0CS, Pettaway\u00a0CA, Pagliaro\u00a0LC (2014) Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 113(6):871\u2013877","journal-title":"BJU Int"},{"issue":"1","key":"2753_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.urolonc.2018.10.016","volume":"37","author":"KB Huang","year":"2019","unstructured":"Huang\u00a0KB, Liu\u00a0RY, Peng\u00a0QH et\u00a0al (2019) EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis. Urol Oncol 37(1):71\u201377","journal-title":"Urol Oncol"},{"issue":"1","key":"2753_CR55","first-page":"32","volume":"115","author":"MR Raspollini","year":"2022","unstructured":"Raspollini\u00a0MR, Comperat\u00a0EM, Lopez-Beltran\u00a0A et\u00a0al (2022) News in the classification of WHO 2022 bladder tumors. Pathologica 115(1):32\u201340","journal-title":"Pathologica"},{"key":"2753_CR56","first-page":"100661","volume":"33","author":"EM Yu","year":"2022","unstructured":"Yu\u00a0EM, Belay\u00a0S, Li\u00a0W, Aragon-Ching\u00a0JB (2022) Non-urothelial and urothelial variants of bladder cancer. Cancer Treat Res Commun 33:100661","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"2753_CR57","doi-asserted-by":"publisher","first-page":"107327481880026","DOI":"10.1177\/1073274818800269","volume":"25","author":"A Minato","year":"2018","unstructured":"Minato\u00a0A, Noguchi\u00a0H, Tomisaki\u00a0I et\u00a0al (2018) Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder. Cancer Control 25(1):1073274818800269","journal-title":"Cancer Control"},{"issue":"2","key":"2753_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00345-019-02771-1","volume":"38","author":"X Lin","year":"2020","unstructured":"Lin\u00a0X, Deng\u00a0T, Wu\u00a0S, Lin\u00a0SX, Wang\u00a0D, Wu\u00a0CL (2020) The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a\u00a0meta-analysis. World J Urol 38(2):323\u2013333","journal-title":"World J Urol"},{"issue":"1","key":"2753_CR59","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12885-019-5924-6","volume":"19","author":"L Zhang","year":"2019","unstructured":"Zhang\u00a0L, Wu\u00a0B, Zha\u00a0Z, Qu\u00a0W, Zhao\u00a0H, Yuan\u00a0J (2019) Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a\u00a0systematic review and meta-analysis. BMC Cancer 19(1):716","journal-title":"BMC Cancer"},{"issue":"6","key":"2753_CR60","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/JU.0000000000001305","volume":"204","author":"K Mori","year":"2020","unstructured":"Mori\u00a0K, Abufaraj\u00a0M, Mostafaei\u00a0H et\u00a0al (2020) A\u00a0Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. J\u00a0Urol 204(6):1129\u20131140","journal-title":"J Urol"},{"key":"2753_CR61","unstructured":"van der Heijden AG, Bruins HM, Carrion A et\u00a0al (2025) Muscle-invasive and Metastatic Bladder Cancer. EAU Guidelines Edn presented at the EAU Annual Congress Madrid 2025. Arnhem, The Netherlands.: EAU Guidelines Office. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/;"},{"issue":"1","key":"2753_CR62","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.clgc.2023.07.005","volume":"22","author":"DK Kim","year":"2024","unstructured":"Kim\u00a0DK, Kim\u00a0JH, Park\u00a0JY et\u00a0al (2024) Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology: A\u00a0Systematic Review and Meta-Analysis of Survival Outcomes and Pathological Features. Clin Genitourin Cancer 22(1):e53\u2013e65 (e1)","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2753_CR63","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/JU.0000000000003836","volume":"211","author":"Y Allory","year":"2024","unstructured":"Allory\u00a0Y, Culine\u00a0S, Krucker\u00a0C, Fontugne\u00a0J, Harter\u00a0V, Pfister\u00a0C (2024) Impact of Divergent Differentiation and\/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial. J\u00a0Urol 211(4):564\u2013574","journal-title":"J Urol"},{"issue":"10","key":"2753_CR64","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Valderrama\u00a0BP, Gupta\u00a0S et\u00a0al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N\u00a0Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"21","key":"2753_CR65","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot\u00a0Y, Matsubara\u00a0N, Park\u00a0SH et\u00a0al (2023) Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N\u00a0Engl J Med 389(21):1961\u20131971","journal-title":"N Engl J Med"},{"issue":"13","key":"2753_CR66","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles\u00a0T, Park\u00a0SH, Voog\u00a0E et\u00a0al (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N\u00a0Engl J Med 383(13):1218\u20131230","journal-title":"N Engl J Med"},{"issue":"5","key":"2753_CR67","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto\u00a0GJ, Amin\u00a0MB, Berney\u00a0DM et\u00a0al (2022) The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part\u00a0B:\u00a0Prostate and Urinary Tract Tumors. Eur Urol 82(5):469\u2013482","journal-title":"Eur Urol"},{"issue":"6","key":"2753_CR68","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/S0022-5347(06)00317-X","volume":"175","author":"CG Rogers","year":"2006","unstructured":"Rogers\u00a0CG, Palapattu\u00a0GS, Shariat\u00a0SF et\u00a0al (2006) Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J\u00a0Urol 175(6):2048\u20132053 (discussion 53)","journal-title":"J Urol"},{"issue":"2","key":"2753_CR69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0022-5347(01)64487-2","volume":"158","author":"MA Ghoneim","year":"1997","unstructured":"Ghoneim\u00a0MA, el-Mekresh\u00a0MM, el-Baz\u00a0MA, el-Attar\u00a0IA, Ashamallah\u00a0A (1997) Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J\u00a0Urol 158(2):393\u2013399","journal-title":"J Urol"},{"key":"2753_CR70","doi-asserted-by":"crossref","unstructured":"Kwon WA, Seo HK, Song G, Lee MK, Park WS (2025) Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development. Biomedicines 13(1)","DOI":"10.3390\/biomedicines13010086"},{"issue":"2","key":"2753_CR71","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","volume":"77","author":"JA Witjes","year":"2020","unstructured":"Witjes\u00a0JA, Babjuk\u00a0M, Bellmunt\u00a0J et\u00a0al (2020) EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(dagger): Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 77(2):223\u2013250","journal-title":"Eur Urol"},{"issue":"4","key":"2753_CR72","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.eururo.2020.01.003","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi\u00a0A, Madison\u00a0R, Raggi\u00a0D et\u00a0al (2020) Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. Eur Urol 77(4):548\u2013556","journal-title":"Eur Urol"},{"issue":"7","key":"2753_CR73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2019.37.7_suppl.399","volume":"37","author":"F Anari","year":"2019","unstructured":"Anari\u00a0F, Miron\u00a0B, Henson\u00a0D et\u00a0al (2019) Non-urothelial bladder cancer: Genomic alterations and patient outcomes. JCO 37(7):399","journal-title":"JCO"},{"key":"2753_CR74","doi-asserted-by":"publisher","first-page":"e2100392","DOI":"10.1200\/PO.21.00392","volume":"6","author":"N Almassi","year":"2022","unstructured":"Almassi\u00a0N, Whiting\u00a0K, Toubaji\u00a0A et\u00a0al (2022) Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precis Oncol 6:e2100392","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"2753_CR75","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00428-020-02787-8","volume":"477","author":"A Maurer","year":"2020","unstructured":"Maurer\u00a0A, Ortiz-Bruechle\u00a0N, Guricova\u00a0K et\u00a0al (2020) Comparative genomic profiling of glandular bladder tumours. Virchows Arch 477(3):445\u2013454","journal-title":"Virchows Arch"},{"issue":"2","key":"2753_CR76","doi-asserted-by":"publisher","first-page":"e471924","DOI":"10.1200\/EDBK-25-471924","volume":"45","author":"KK Zarrabi","year":"2025","unstructured":"Zarrabi\u00a0KK, Saxena\u00a0A, Mouw\u00a0KW, Koshkin\u00a0VS, Friedlander\u00a0T (2025) Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma. Am Soc Clin Oncol Educ Book 45(2):e471924","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2753_CR77","doi-asserted-by":"publisher","first-page":"104524","DOI":"10.1016\/j.critrevonc.2024.104524","volume":"204","author":"A Peddio","year":"2024","unstructured":"Peddio\u00a0A, Pietroluongo\u00a0E, Lamia\u00a0MR et\u00a0al (2024) DLL3 as a\u00a0potential diagnostic and therapeutic target in neuroendocrine neoplasms: A\u00a0narrative review. Crit Rev Oncol Hematol 204:104524","journal-title":"Crit Rev Oncol Hematol"},{"issue":"20","key":"2753_CR78","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Klumper","year":"2024","unstructured":"Klumper\u00a0N, Tran\u00a0NK, Zschabitz\u00a0S et\u00a0al (2024) NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J\u00a0Clin Oncol 42(20):2446\u20132455","journal-title":"J Clin Oncol"},{"issue":"8","key":"2753_CR79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","volume":"29","author":"JH Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits\u00a0JH, Lombardo\u00a0KA, Parimi\u00a0V et\u00a0al (2021) Expression of Nectin\u20114 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. Appl Immunohistochem Mol Morphol 29(8):619\u2013625","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02753-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:03:54Z","timestamp":1770822234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02753-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02753-9","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"8 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Rausch, I.\u00a0Heidegger, J.\u00a0Linxweiler, C.\u00a0Becker und G.\u00a0Niegisch geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}